Sunitinib malate and Etoposide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Sunitinib malate (sunitinib malate) and Etoposide (etoposide). Common drug interactions include neoplasm progression among females and second primary malignancy among males.

The phase IV clinical study analyzes what interactions people have when they take Sunitinib malate and Etoposide. It is created by eHealthMe based on reports of 14 people who take the same drugs from the FDA, and is updated regularly.

What is Sunitinib malate?

Sunitinib malate has active ingredients of sunitinib malate. eHealthMe is studying from 9,160 Sunitinib malate users. Check the latest studies of Sunitinib malate.

What is Etoposide?

Etoposide has active ingredients of etoposide. eHealthMe is studying from 77,815 Etoposide users. Check the latest studies of Etoposide.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 28, 2026

14 people who take Sunitinib malate and Etoposide together, and have interactions are studied.

Sunitinib malate and Etoposide drug interactions.

What are the common drug interactions of Sunitinib Malate and Etoposide, by gender? *:

female:

Neoplasm progression (growth of tumour)
Thrombocytopenia (decrease of platelets in blood)
Disease progression
Metastases to liver (cancer spreads to liver)
Sensory loss (senses loss)
Neutropenic infection (infection with less neutrophil numbers in blood)
Sudden death
Anaemia (lack of blood)
Death
Drug ineffective

male:

Second primary malignancy (after getting cure a cancer, a new cancer development)
Chronic kidney disease
Nephropathy toxic (damage to kidney due to toxins)

What are the common drug interactions of Sunitinib Malate and Etoposide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Anaemia (lack of blood)
Death
Drug ineffective
Febrile neutropenia (fever with reduced white blood cells)
Leukaemia recurrent (repeat cancer of bone marrow or blood cells)
Thrombocytopenia (decrease of platelets in blood)

30-39:

Neutropenic infection (infection with less neutrophil numbers in blood)
Neoplasm progression (growth of tumour)
Disease progression
Sensory loss (senses loss)

40-49:

n/a

50-59:

n/a

60+:

Second primary malignancy (after getting cure a cancer, a new cancer development)
Sudden death
Anaemia (lack of blood)
Chronic kidney disease
Metastases to liver (cancer spreads to liver)
Nephropathy toxic (damage to kidney due to toxins)

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 5 people, 35.71%
Thymic Cancer Metastatic: 4 people, 28.57%
Lung Cancer - Non-Small Cell (lung cancer): 4 people, 28.57%
Neoplasm Malignant (cancer tumour): 3 people, 21.43%
Pancreatic Neuroendocrine Tumor: 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Sunitinib malate and Etoposide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously